Should I continue low‑dose aspirin (81 mg daily) after 15 years of use for colorectal cancer prevention?

Should You Continue Low-Dose Aspirin After 15 Years for Colorectal Cancer Prevention?

After 15 years of continuous low-dose aspirin use, you have already achieved the maximum colorectal cancer prevention benefit, and continuing aspirin should now be based primarily on your current cardiovascular risk and bleeding risk profile rather than additional cancer prevention gains.

The Evidence on Long-Term Aspirin Use

The USPSTF 2016 guidelines establish that colorectal cancer prevention benefits require at least 5-10 years of aspirin use to become apparent, with maximum benefit observed after 10-15 years 1. After 15 years of use, you have crossed the threshold where cancer prevention benefits plateau.

Key Findings on Duration:

• Cancer benefit timing: CRC risk reduction becomes evident only after 10 years of aspirin therapy 1
• Long-term data: 20-year follow-up studies show that aspirin taken for ≥5 years reduces long-term CRC incidence (HR 0.76) and mortality (HR 0.65), with greatest benefit for proximal colon cancers 2
• Recent cohort data: A 2024 Danish study of nearly 2 million people found that long-term (≥5-10 years) low-dose aspirin use was associated with 10-30% reductions in risk for multiple cancer sites including colon and rectum 3
• Very recent evidence: A 2026 Cochrane review found very low-certainty evidence suggesting potential CRC incidence reduction (HR 0.78) and mortality benefit only at ≥15 years follow-up, but noted these benefits emerged during observational phases where treatment contamination limits interpretation 4

Critical Decision Framework After 15 Years

1. Assess Your Current 10-Year Cardiovascular Risk

Calculate your ACC/AHA 10-year CVD risk using factors: age, sex, race/ethnicity, cholesterol levels, blood pressure, diabetes status, and smoking 1.

• If ≥10% CVD risk AND age 50-69: Continue aspirin—the cardiovascular benefit now becomes the primary justification, with prior cancer prevention as an added historical benefit 1
• If <10% CVD risk OR age ≥70: The benefit-harm balance shifts unfavorably; strongly consider discontinuation 1

2. Evaluate Your Bleeding Risk Profile

High-risk features that favor discontinuation 1:

• Age ≥70 years (bleeding risk increases substantially)
• Male sex (2× higher GI bleeding risk)
• History of GI ulcers or upper GI pain
• Concurrent NSAID use (increases serious GI bleeding 2-3× compared to aspirin alone)
• Concurrent anticoagulation
• Uncontrolled hypertension
• History of bleeding disorders

The evidence is clear: aspirin increases serious extracranial hemorrhage risk (RR 1.59) and hemorrhagic stroke risk (OR 1.40) 4. These harms are immediate and certain, while any additional cancer benefit beyond 15 years is uncertain.

3. Consider Your Life Expectancy

The USPSTF framework requires life expectancy ≥10 years to justify aspirin initiation 1. However, after 15 years of use:

• You've already captured the cancer prevention benefit
• Continuing aspirin for cardiovascular protection requires reassessing whether you'll live long enough to benefit from CVD risk reduction
• If life expectancy <10 years due to comorbidities, discontinuation is reasonable

The Nuanced Reality: What the Guidelines Don't Explicitly Address

The 2016 USPSTF guidelines focus on initiating aspirin, not on when to stop after long-term use 1. This creates a clinical gap. Here's how to navigate it:

For patients age 50-69 with ≥10% CVD risk who have taken aspirin for 15 years:

• The original indication (combined CVD + CRC prevention) has been fulfilled for the cancer component
• Continue aspirin if cardiovascular benefit alone justifies ongoing use (essentially treating this as secondary prevention of CVD events)
• Discontinue if bleeding risk factors have emerged or accumulated (age-related risk increase, new medications, new comorbidities)

For patients age ≥70 who have taken aspirin for 15 years:

• The USPSTF states "insufficient evidence" for this age group 1
• Bleeding risk increases substantially with age 1
• Strongly consider discontinuation unless there is compelling cardiovascular indication (e.g., prior MI or stroke, which would shift this to secondary prevention)

Common Pitfalls to Avoid

1. Don't assume "more is better": There's no evidence that continuing aspirin beyond 15 years provides incremental cancer prevention benefit 4, 2

2. Don't ignore accumulated bleeding risk: Risk factors accumulate over time (aging, new medications, new conditions). Reassess annually 1

3. Don't use enteric-coated formulations expecting reduced bleeding: No evidence supports that enteric-coated or buffered aspirin reduces serious GI bleeding risk 1

4. Don't continue aspirin solely for cancer prevention at this point: The cancer benefit has been achieved; ongoing use must be justified by cardiovascular considerations 1

Practical Algorithm for Your Decision

After 15 years of low-dose aspirin:

├─ Age <70 AND 10-year CVD risk ≥10% AND no high bleeding risk?
│  └─ YES → Continue aspirin (primary justification now cardiovascular)
│  └─ NO → Proceed to next step
│
├─ Age ≥70 OR 10-year CVD risk <10%?
│  └─ YES → Strongly consider discontinuation
│  └─ NO → Proceed to next step
│
└─ High bleeding risk features present?
   └─ YES → Discontinue aspirin
   └─ NO → Individualized decision with shared decision-making

The Bottom Line

You have already obtained the colorectal cancer prevention benefit from 15 years of aspirin use. The decision to continue should pivot to whether ongoing cardiovascular protection justifies the bleeding risk, which increases with age and comorbid conditions. If you are under 70 with ≥10% CVD risk and no significant bleeding risk factors, continuation is reasonable 1. If you are 70 or older, have lower CVD risk, or have accumulated bleeding risk factors, discontinuation is the safer choice 1, 4.

Most importantly: This decision requires reassessment of your current clinical status, not just continuation by inertia. The cancer prevention ship has sailed successfully—now evaluate whether the cardiovascular benefit justifies ongoing exposure to bleeding risk.